GlassScriptPhysician profile
Stacey R King
NPI 1598146631
$4,005.26
in general payments reported to CMS, 2019-2025
22 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $899 · 2022: $1,504 · 2023: $838 · 2024: $624 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,602.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $694.45 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $640.52 | 2021-2025 | |
| Abbvie INC. | $584.97 | 2021-2023 | |
| Lilly USA, LLC | $522.77 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Corium, LLC | $234.51 | 2023-2025 | Azstarys |
| Novartis Pharmaceuticals Corporation | $188.90 | 2021-2022 | |
| Glaxosmithkline, LLC. | $171.05 | 2021-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $163.29 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.14 | 2021-2024 | Xifaxan, Trulance |
| Abbott Laboratories | $151.57 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $81.02 | 2021-2022 | |
| Pfizer INC. | $80.84 | 2021-2023 | |
| Amarin Pharma, INC. | $67.34 | 2021-2022 | |
| Genentech USA, INC. | $56.68 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $54.04 | 2022-2023 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $33.36 | 2022-2024 | Repatha |
| Almatica Pharma LLC | $28.20 | 2021-2022 | |
| Neos Therapeutics, LP | $24.62 | 2022 | |
| Hikma Pharmaceuticals USA | $17.82 | 2024 | Ryaltris |
| Ibsa Pharma INC. | $17.80 | 2023 | Tirosint, Licart |
| Tris Pharma INC | $15.11 | 2023 | Dyanavel Xr |
| Mylan Specialty L.P. | $14.26 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.